PharmaEssentia Wins US, Japan Approvals for Ropeg to Treat Essential Thrombocythemia
PharmaEssentia secured US and Japanese approvals in August for BESREMi (ropeginterferon alfa-2b) to treat essential thrombocythemia. BESREMi is the only FDA-approved drug for both essential thrombocythemia and polycythemia vera. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative arti